AditxtScore for COVID-19 is being offered in Great Lakes Medical Laboratory (GLML) locations, allowing Michiganders and their physicians to monitor and evaluate their COVID-19 immune response. The AditxtScore for COVID-19 is a comprehensive immune response monitoring that tracks multiple combinations of antibody and neutralizing antibody responses against several different antigens. This makes it possible to assess the strength of an individual’s immune response to the SARS-CoV-2 virus.
Under the agreement, GLML will make the AditxtScore for COVID-19 available throughout its six physical locations and mobile units in select areas in Michigan. The initiative is part of Aditxt’s ongoing effort to expand its immune monitoring network nationwide.
“We were drawn to Aditxt initially because it has the most comprehensive COVID-19 immune testing solution available, allowing us to give people certainty about their individual immune response to COVID-19,” says Elizabeth Knisely, chief executive officer of GLML. “What I did not expect was that after receiving an AditxtScore myself I would find that I have had low immune response, despite being vaccinated. With so much uncertainty out there right now around a surge in breakthrough cases, we need to take the guesswork out of the equation especially for patients who are vulnerable and immunocompromised.”
AditxtScore for COVID-19, which was first introduced in August 2020, differentiates itself from traditional antibody tests by delivering a detailed view of an individual’s immune response to multiple antigens associated with the SARS-CoV-2 virus. This multi-multiplex approach to capturing the full spectrum of biomarkers associated with SARS-CoV-2 delivers a highly detailed snapshot of an individual’s immune response in a single test cycle. It also includes the ability to measure neutralizing antibodies, the subset of virus-specific antibodies that block infection by interfering with cell entry of virus particles. The level of precision in AditxtScore for COVID-19, along with its ability to measure the neutralizing activity of IgG, IgM and IgA isotopes, can provide clinicians with the data they need to understand the strength and quality of each individual’s immune response to COVID-19, whether through exposure and infection or vaccination.
“While we have seen relatively strong vaccine uptake in Michigan, just under half of our population is still not vaccinated and vaccine hesitancy remains a significant challenge in our rural and urban areas,” says Samar Nasry, MD, internal medicine specialist and director of the Medical Care1 Urgent Care, Michigan. “A lot of the hesitancy we’re seeing is driven by misinformation, potential infection post vaccination, and uncertainty about individual risk. The wide availability of the AditxtScore for COVID-19 will help us address those challenges by giving people the hard facts about their immune status, helping them to make informed decisions about immunization.”
This information is particularly important for the millions of immunocompromised patients who may not develop an adequate immune response to vaccination or exposure for multiple reasons, including: immunosuppressive disease, immunosuppressant medications, anti-cancer medications affecting immune function, or the presence of long-term chronic disease that has exhausted the body’s natural immune response capacity.
“We’re thrilled to be working with GLML to bring our AditxtScore for COVID-19 to the state of Michigan,” says Amro Albanna, co-founder and chief executive officer of Aditxt. “Everyone’s immune response is unique to that individual, so it’s critical to evaluate each individual’s immune response in order to effectively address this pandemic. Our AditxtScore for COVID-19 delivers that personalized approach with the accessibility and efficiency needed to scale.”
To find an AditxtScore Channel Partner near you, please visit AditxtScore. AditxtScore for COVID-19 is available for use as a CLIA-validated laboratory developed test (LDT). This test is not for self-diagnosis and is not cleared or approved by the FDA.
